Momenta plans exit of Mylan biosimilars

 
• By Dean Rudge
  
Generate a summary of this article
Listen to this article
Beta

Momenta Pharmaceuticals has “initiated discussions” with partner Mylan to exit its participation in the development of five biosimilar programs, including the firms’ M834 biosimilar Orencia (abatacept) candidate, after completing a strategic review “aimed at reducing costs of biosimilar development” and focusing its resources on its pipeline of novel drug candidates.

Momenta Pharmaceuticals has “initiated discussions” with partner Mylan to exit its participation in the development of five biosimilar programs, including the firms’ M834 biosimilar Orencia (abatacept) candidate, after completing a strategic review “aimed at reducing costs of biosimilar development” and focusing its resources on its pipeline of novel drug candidates.

“As a result, Momenta plans to advance two late-stage biosimilar assets, M923, its wholly-owned proposed biosimilar to Humira (adalimumab) and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Archive

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Prescribed Medications for Attention Deficit Hyperactivity Disorder) - Clone - Clone

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Testing-Rising

 
• By Saba Afreen

Testing-Rising xxxx

bhvyuguig

lnkbkb

test 1

test 1

More from Generics Bulletin

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C10

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C9

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By Reed Miller

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.